Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Protagonist Therapeutics Inc. (PTGX:NASDAQ), powered by AI.
Protagonist Therapeutics Inc. is currently trading at $133.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Protagonist Therapeutics Inc. on Alpha Lenz.
Protagonist Therapeutics Inc.'s P/E ratio is -65.0.
“Protagonist Therapeutics Inc. trades at a P/E of -65.0 (undervalued) with modest ROE of -20.2%. 3Y revenue CAGR of 20.1% highlights clear growth momentum.”
Ask for details →Protagonist Therapeutics Inc. is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. These therapeutics are designed to address significant unmet medical needs, focusing on diseases that involve critical biological pathways regulated by peptides and proteins. Utilizing a proprietary technology platform, Protagonist Therapeutics develops solutions for conditions such as inflammatory bowel disease, myeloproliferative neoplasms, and other serious health disorders. The company’s innovative approach aims to combine the efficacy and safety of peptide drugs with novel mechanisms of action, providing targeted treatments that can potentially improve patient outcomes. Located in Newark, California, Protagonist Therapeutics plays a vital role in the biotechnology industry, contributing to advances in medical treatments and the broader healthcare sector. Its research and development efforts are significant, offering potential new therapies that could positively impact both patients’ lives and healthcare practices.
“Protagonist Therapeutics Inc. trades at a P/E of -65.0 (undervalued) with modest ROE of -20.2%. 3Y revenue CAGR of 20.1% highlights clear growth momentum.”
Ask for details →Protagonist Therapeutics Inc. (ticker: PTGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $8.5B.
The current price is $133 with a P/E ratio of -64.97x and P/B of 13.75x.
ROE is -20.18% and operating margin is -343.63%. Annual revenue is $46M.